Answers are grounded in this paper and cite their sources.
SUMMARY The purpose of this overview is to collect available literature on the use of recombinant activated factor VII (rFVIIa) in conjunction with orthopedic surgery, and to describe and discuss the efficacy of rFVIIa in such procedures. The review deals with surgical procedures carried out in patients with hemophilia complicated by the presence of inhibitors (alloantibodies) against the missing coagulation factor as well as procedures carried out in persons with no pre‐existing coagulation disorder. One randomized controlled clinical trial has been performed in hemophilia patients with inhibitors, but no other controlled studies were identified. Data collected show that rFVIIa is highly efficacious in the prevention and management of surgical bleeds in most hemophilia patients with inhibitors when frequent bolus injections of 100 µg/kg body weight of rFVIIa was adopted, while data from cases managed with a continuous infusion technology were less clear. In particular, the optimal infusion rate of rFVIIa needs clarification. In orthopedic patients with no known pre‐existing coagulation disorder, data gathered during the review show that rFVIIa reduces the blood loss in severe blunt trauma, while the effect on bleeding by rFVIIa in elective orthopedic procedures needs further clarification.
No takes yet. Share an insight, caveat, or question.
Ingerslev et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: